Literature DB >> 15099755

Analysis of the HIV-1 gp41 specific immune response using a multiplexed antibody detection assay.

David Opalka1, Antonello Pessi, Elisabetta Bianchi, Gennaro Ciliberto, William Schleif, Michael McElhaugh, Renee Danzeisen, Romas Geleziunas, Michael Miller, Debra M Eckert, David Bramhill, Joseph Joyce, James Cook, William Magilton, John Shiver, Emilio Emini, Mark T Esser.   

Abstract

A fluorescence-based, multiplexed, antibody-binding and mapping assay was developed to characterize antibody responses in HIV-1-infected individuals to the ectodomain of the HIV-1 gp41 envelope glycoprotein. The antigen panel included intact recombinant gp41, the fusion peptide region, the polar region, the N-heptad region, the C-heptad region as well as overlapping epitopes in the 2F5 and 4E10 monoclonal antibody-binding regions. The panel included both native and constrained peptides specifically designed to mimic putative gp41 prefusion and fusion intermediates. The results of these analyses revealed a broad pattern of immune responses against the test antigens, suggesting that none of these gp41 regions are immunologically silent. The HIV-1-positive sera were also evaluated using infectivity inhibition assays. No correlation was evident between the breadth or magnitude of specific anti-gp41 reactivities and virus neutralization potency. These evaluations demonstrated the substantial potential of the multiplexed antibody binding and mapping assay for rapid and sensitive analysis of complex antibody responses.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15099755     DOI: 10.1016/j.jim.2004.01.016

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  18 in total

1.  Anti-human immunodeficiency virus type 1 (HIV-1) antibodies 2F5 and 4E10 require surprisingly few crucial residues in the membrane-proximal external region of glycoprotein gp41 to neutralize HIV-1.

Authors:  Michael B Zwick; Richard Jensen; Sarah Church; Meng Wang; Gabriela Stiegler; Renate Kunert; Hermann Katinger; Dennis R Burton
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

Review 2.  The membrane-proximal external region of the human immunodeficiency virus type 1 envelope: dominant site of antibody neutralization and target for vaccine design.

Authors:  Marinieve Montero; Nienke E van Houten; Xin Wang; Jamie K Scott
Journal:  Microbiol Mol Biol Rev       Date:  2008-03       Impact factor: 11.056

3.  Characterization of the steric defense of the HIV-1 gp41 N-trimer region.

Authors:  Debra M Eckert; Yu Shi; Sunghwan Kim; Brett D Welch; Eunchai Kang; Emily S Poff; Michael S Kay
Journal:  Protein Sci       Date:  2008-09-18       Impact factor: 6.725

4.  Immunogenicity of recombinant human immunodeficiency virus type 1-like particles expressing gp41 derivatives in a pre-fusion state.

Authors:  Mikyung Kim; Zhisong Qiao; Jessica Yu; David Montefiori; Ellis L Reinherz
Journal:  Vaccine       Date:  2006-10-09       Impact factor: 3.641

5.  Anti-gp41 antibodies cloned from HIV-infected patients with broadly neutralizing serologic activity.

Authors:  John Pietzsch; Johannes F Scheid; Hugo Mouquet; Michael S Seaman; Christopher C Broder; Michel C Nussenzweig
Journal:  J Virol       Date:  2010-03-10       Impact factor: 5.103

6.  Multiplexed detection of antibodies using programmable bead arrays.

Authors:  Karen S Anderson
Journal:  Methods Mol Biol       Date:  2011

7.  Factors associated with the development of cross-reactive neutralizing antibodies during human immunodeficiency virus type 1 infection.

Authors:  D Noah Sather; Jakob Armann; Lance K Ching; Angeliki Mavrantoni; George Sellhorn; Zachary Caldwell; Xuesong Yu; Blake Wood; Steve Self; Spyros Kalams; Leonidas Stamatatos
Journal:  J Virol       Date:  2008-11-05       Impact factor: 5.103

8.  Antibody elicited against the gp41 N-heptad repeat (NHR) coiled-coil can neutralize HIV-1 with modest potency but non-neutralizing antibodies also bind to NHR mimetics.

Authors:  Josh D Nelson; Heather Kinkead; Florence M Brunel; Dan Leaman; Richard Jensen; John M Louis; Toshiaki Maruyama; Carole A Bewley; Katherine Bowdish; G Marius Clore; Philip E Dawson; Shana Frederickson; Rose G Mage; Douglas D Richman; Dennis R Burton; Michael B Zwick
Journal:  Virology       Date:  2008-05-21       Impact factor: 3.616

9.  Serologic assay to quantify human immunoglobulin G antibodies to the Staphylococcus aureus iron surface determinant B antigen.

Authors:  Michael D Raedler; Samantha Heyne; Erica Wagner; Sheri K Shalkowski; Susan Secore; Annaliesa S Anderson; James Cook; Leslie Cope; Tessie McNeely; Mary Retzlaff; Jon Shanter; Leonard J Rubinstein; Tina Green; N Kartsonis; Mark T Esser
Journal:  Clin Vaccine Immunol       Date:  2009-03-25

10.  Rapid detection of antibodies in sera using multiplexed self-assembling bead arrays.

Authors:  Jessica Wong; Sahar Sibani; Naa Norkor Lokko; Joshua LaBaer; Karen S Anderson
Journal:  J Immunol Methods       Date:  2009-09-02       Impact factor: 2.303

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.